Get the Stockscreener App
196.46
0.19%
0.38
After Hours:
196.46
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $196.46, with a volume of 675.51K.
It is up +0.19% in the last 24 hours and down -5.46% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$196.08
Open:
$196.77
24h Volume:
675.51K
Relative Volume:
0.70
Market Cap:
$21.58B
Revenue:
$11.04B
Net Income/Loss:
$1.04B
P/E Ratio:
22.42
EPS:
8.7626
Net Cash Flow:
$1.36B
1W Performance:
+0.63%
1M Performance:
-5.46%
6M Performance:
+5.97%
1Y Performance:
+18.59%
1-Day Range:
$194.28
$197.72
1-Week Range:
$192.79
$202.91
52-Week Range:
$157.20
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
196.46 | 21.54B | 11.04B | 1.04B | 1.36B | 8.7626 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quest Diagnostics (DGX) down 4.2% since last earnings report: Can it rebound? - MSN
8,744 Shares in Quest Diagnostics Incorporated $DGX Acquired by Union Bancaire Privee UBP SA - MarketBeat
Paradiem LLC Buys New Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics to Report Q1 2026 Financial Results on April 21 - Intellectia AI
Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026 - GuruFocus
Quest Diagnostics schedules April 21 earnings release, 8:30 a.m. call - Stock Titan
How Is Quest Diagnostics’ Stock Performance Compared to Other Healthcare Stocks? - Yahoo Finance
Davis Selected Advisers Acquires 7,192 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Zacks Industry Outlook Features Quest Diagnostics, DaVita, Option Care Health, and Addus HomeCare - Bitget
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare - Zacks Investment Research
Danica Pension Livsforsikringsaktieselskab Buys Shares of 70,846 Quest Diagnostics Incorporated $DGX - MarketBeat
Achmea Investment Management B.V. Grows Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts - TradingView
Quest Diagnostics Incorporated $DGX Shares Sold by Chevy Chase Trust Holdings LLC - MarketBeat
Aquatic Capital Management LLC Has $8.06 Million Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
EdgePoint Investment Group Inc. Grows Position in Quest Diagnostics Incorporated $DGX - MarketBeat
CSM Advisors LLC Sells 20,078 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Crawford Investment Counsel Inc. Purchases 9,473 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Position Increased by 8 Knots Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Sees Large Decrease in Short Interest - MarketBeat
iSAM Funds UK Ltd Invests $1.47 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Integral Health Asset Management LLC Sells 65,000 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Wentworth to Board of Directors - New Jersey Business Magazine
Korea Investment CORP Sells 14,900 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors - Sahm
Quest Diagnostics adds ex-Walgreens CEO to board By Investing.com - Investing.com India
Quest Diagnostics Elects Former Walgreens Boots Alliance CEO Timothy Wentworth to Board of Directors - Minichart
Quest Diagnostics (DGX) Appoints Timothy Wentworth to Board of D - GuruFocus
Quest Diagnostics names Timothy Wentworth to board, joins Compensation and Quality Committees - TradingView
Quest Diagnostics adds ex-Walgreens CEO to board - Investing.com
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors – Company AnnouncementFT.com - Financial Times
Quest Diagnostics (DGX) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Swiss National Bank Reduces Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Director at Quest Diagnostics (NYSE: DGX) gets 215 RSUs - Stock Titan
Quest Diagnostics (DGX) director Timothy Wentworth files insider Form 3 - Stock Titan
Quest Diagnostics Incorporated $DGX Position Trimmed by Schroder Investment Management Group - MarketBeat
Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test - simplywall.st
First Trust Advisors LP Raises Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Banque Cantonale Vaudoise Acquires 5,985 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Should You Keep DGX Shares in Your Investment Portfolio? - Bitget
Should You Continue to Hold DGX Stock in Your Portfolio? - The Globe and Mail
Barclays PLC Has $47.86 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Incorporated $DGX Shares Purchased by Blair William & Co. IL - MarketBeat
Quest Diagnostics earnings bolstered by March rebound, sending stock up 3% - MSN
Plewman Patrick, Quest Diagnostics SVP, sells $588k in stock By Investing.com - Investing.com India
Implied volatility surging for Quest Diagnostics stock options - MSN
Insider Selling: Quest Diagnostics (NYSE:DGX) EVP Sells $1,146,115.18 in Stock - MarketBeat
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):